Abstract
The process of bringing a drug through early development and on through a successful clinical trials campaign is long and complex. This chapter provides an overview of the drug development process and some of the challenges and pitfalls that can be encountered on the path to marketing approval for a sustained-release intraocular drug delivery system. In general, the drug development process proceeds from exploratory analyses of new compounds, through preclinical and clinical testing of promising drug candidates, to application for marketing approval in one or more markets. Although the application for marketing approval is the final step, success depends on taking the requirements for obtaining marketing approval into consideration early in the process and initiating communication with the relevant regulatory agency(s) while the candidate drug is still in preclinical testing. A successful preclinical development program should be designed to provide all the information needed to determine if the drug is appropriate for further testing in human subjects. Approval to begin human testing (phase I trials) is only granted if there is sufficient evidence of drug safety, if the pharmacologic profile of the drug is appropriate for the condition it is proposed to treat, and the clinical trial design submitted is sufficient to ensure the safety of the human subjects. Clinical testing, if approved, proceeds through phase I (to evaluate safety and dosing considerations), to phase II (early investigations of efficacy and further exploration of dose–response), and finally to phase III (definitive investigations of safety and efficacy in the intended patient population). If the results of the clinical trials demonstrate sufficient safety and efficacy, the drug developer can apply for marketing approval in the United States (US) through the Food and Drug Administration (FDA) or in the European Union (EU) through one of three separate pathways to approval—the centralized, decentralized, or mutual recognition procedures. In all cases, the success of an application will depend not only on the merits of the drug itself but also on how well the drug development program was designed to meet the concerns and requirements of the appropriate regulatory agency(s). The single most effective way to ensure that a drug application meets these requirements and concerns is through early and frequent consultation with the appropriate regulatory agency contacts.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Black LE, Bendele AM, Bendele RA, Zack PM, Hamilton M (1999) Regulatory decision strategy for entry of a novel biological therapeutic with a clinically unmonitorable toxicity into clinical trials: pre-IND meetings and a case example. Toxicol Pathol 27(1):22–26
Food and Drug Administration Website. Drugs @FDA: (http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm)
European Medicines Agency Website. Human medicines: (http://www.ema.europa.eu/ema/index.jsp?curl = pages/regulation/landing/human_medicines_regulatory.jsp&mid = WC0b01ac058001ff89)
Kohler M (2011) Regulatory pathways in the European Union. MAbs 3(3):241–242
International Conference on Harmonisation Website (http://www.ich.org/)
Food and Drug Administration Website. Investigational new drug application (http://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/investigationalnewdrugindapplication/default.htm)
European Medicines Agency (2009) Document CPMP/ICH/286/95: Note for guidance on non-clinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals
Investigational Medicinal Product Dossier Website (http://www.impd.eu/)
International Conference on Harmonisation Website. Safety guidelines (http://www.ich.org/products/guidelines/safety/article/safety-guidelines.html
Food and Drug Administration Website. Drug Development and Review Definitions (http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/InvestigationalNewDrugINDApplication/ucm176522.htm)
European Medicines Agency (1998) Document CPMP/ICH/291/95: Note for guidance on general consideration for clinical trials
Food and Drug Administration, Center for Drug Evaluation and Research (2009) Guidance for industry: End of phase 2A meetings. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM079690.pdf. Accessed on 18 January 2013
Kuppermann BD, Blumenkranz MS, Haller JA et al (2007) Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 125(3):309–317
Demill DL, Wirostko BM, Nelson LA, Stewart JA, Stewart WC (2013) Average versus highest intraocular pressure analyses in glaucoma clinical trials. Ophthalmic Res 49(1):49–51
Miglior S, Bertuzzi F (2013) Relationship between intraocular pressure and glaucoma onset and progression. Curr Opin Pharmacol 13(1):32–35
European Medicines Agency (2012) Document EMA/450332/2012. EU Regulatory Workshop—Ophthalmology—Summary and Report: Clinical Development, Scientific Advice and Paediatric Investigation Plans
McLeod LD, Coon CD, Martin SA, Fehnel SE, Hays RD (2011) Interpreting patient-reported outcome results: US FDA guidance and emerging methods. Expert Rev Pharmacoecon Outcomes Res 11(2):163–169
Vandenbroeck S, De Geest S, Zeyen T, Stalmans I, Dobbels F (2011) Patient-reported outcomes (PRO's) in glaucoma: a systematic review. Eye (Lond) 25(5):555–577
Food and Drug Administration Website. New drug application. (http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/NewDrugApplicationNDA/default.htm)
International Conference on Harmonisation Website. Common technical document (http://www.ich.org/products/ctd.html)
Food and Drug Administration Website. Approval process (http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm289601.htm#review)
Food and Drug Administration Website. Advisory committees (http://www.fda.gov/AdvisoryCommittees/default.htm)
Food and Drug Administration Website. Review process overview (http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm143534.htm)
Congressional Research Service (2001) CRS report for congress. The U.S. drug approval process: a primer
Food and Drug Administration Website. Fast Track, Accelerated Approval and Priority Review (http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/SpeedingAccesstoImportantNewTherapies/ucm128291.htm)
Marchand HC, Ros BJ, Fine AM, Kremzner ME (2012) The U.S. Food and drug administration: drug information resource for formulary recommendations. J Manag Care Pharm 18(9):713–718
Food and Drug Administration Website. Orphan drug designation (http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/default.htm)
European Medicines Agency Website. The centralized process (http://www.ema.europa.eu/ema/index.jsp?curl = pages/about_us/general/general_content_000109.jsp&mid = WC0b01ac0580028a47)
Coordination Group for Mutual Recognition and Decentralised Procedures—Human (2012) Document CMDh/068/1996/Rev8. Best practice guide for decentralized and mutual recognition procedures. (available at: http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/procedural_guidance/Application_for_MA/CMDh_068_1996_Rev8_2012_10-Clean.pdf)
European Commission (2007) Document ENTR/F2/ SM. Volume 2A: Procedures for marketing authorization. Chapter 2: mutual recognition
European Medicines Agency Website. The CHMP (http://www.ema.europa.eu/ema/index.jsp?curl = pages/about_us/general/general_content_000094.jsp&mid = WC0b01ac0580028c79)
European Medicines Agency (2007) Document EMEA/MB/87146/2007. Committee for medicinal products for human use: rules of procedure
Chavan PN, Vijayan S, Joshi MM et al (2011) Marketing authorization procedures in Europe: a regulatory perspective. Int J Pharm Pharmaceut Sci Res 1:13–19
Ozurdex® Prescribing Information. Allergan, Inc. (2012) Available at: http://www.allergan.com/assets/pdf/ozurdex_pi.pdf
Robinson MR, Whitcup SM (2012) Pharmacologic and clinical profile of dexamethasone intravitreal implant. Expert Rev Clin Pharmacol 5(6):629–647
Center for Drug Evaluation and Research (2009) Application number 22–315. Summary review: Ozurdex® for Retinal Vein Occlusion
Center for Drug Evaluation and Research (2010) Supplemental approval letter: Ozurdex® for Uveitis
European Medicines Agency (2011) Document EMA/941595/2011, EMEA/H/C/001140. Ozurdex®: European Public Assessment Report
Haller JA, Bandello F, Belfort R Jr et al (2010) Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 117(6):1134–1146 e1133
Haller JA, Bandello F, Belfort R Jr et al (2011) Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 118(12):2453–2460
Lowder C, Belfort R Jr, Lightman S et al (2011) Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 129(5):545–553
European Medicines Agency Website. About the EMA (http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000235.jsp&mid)
Coordination Group for Mutual Recognition and Decentralised Procedures—Human. Website: About the CMDh (http://www.hma.eu/cmdh.html)
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this protocol
Cite this protocol
Lee, S.S., Robinson, M.R., Whitcup, S.M. (2013). Sustained-Release Ocular Drug Delivery Systems: Bench to Bedside Development. In: Gilger, B. (eds) Ocular Pharmacology and Toxicology. Methods in Pharmacology and Toxicology. Humana Press, Totowa, NJ. https://doi.org/10.1007/7653_2013_3
Download citation
DOI: https://doi.org/10.1007/7653_2013_3
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-744-0
Online ISBN: 978-1-62703-745-7
eBook Packages: Springer Protocols